Basic information Safety Related Supplier

ChemicalBook Product Catalog Evolocumab

1/1

Evolocumab NEW

$397.00 1mg

$588.00 2mg

$945.00 5mg

Min. Order
Purity98.30%
Cas No1256937-27-5
Supply Ability10g
Update time2025-10-15

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

VIP6Y

United States

United States

show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	Evolocumab
CAS No	1256937-27-5
EC-No
Min. Order
Purity	98.30%
Supply Ability	10g
Release date	2025/10/15

Product Introduction

Bioactivity

Name	Evolocumab
Description	Evolocumab is an inhibitor of the humanized monoclonal antibody PCSK9. It binds to circulating PCSK9 protein, resulting in inhibition of PCSK9 binding to LDLR. It can be used in studies of hypercholesterolemia and atherosclerotic cardiovascular disease.
In vitro	METHODS: HUVECs were seeded in 96-well plates at a rate of 1 × 105 cells/well in logarithmic growth phase and treated with evolocumab in the concentration range of 0.5-100 mg/ml or vitamin C (Vit C; 50 and 100 mg /ml), then add new medium, expose HUVECs to 0.5 mM H2O2 for 2 hours, and detect HUVECs cell viability by MTT method. RESULTS* Evolocumab significantly inhibited H2O2-induced cytotoxicity at concentrations of 5-100 mg/ml. [2] METHODS: Rat retinal Müller cells (RMCs) were used as the research object and treated with Evolocumab (100 μg/ml) to study the expression of inflammatory factors in RMCs. RESULTS Evolocumab treatment (100 μg/ml) reduced the expression and secretion of inflammatory factors in stimulated RMCs (P<0.05), downregulated toll-like receptor-4 (TLR-4) levels in RMCs and inhibited nuclear transcription factor-κB ( NF-κB) phosphorylation (P < 0.05).[4]
In vivo	METHODS: In a randomized placebo-controlled clinical study, evolocumab was administered at a dose of 140 mg/2 weeks (Q2W) or 420 mg once a month (QM) for 12 weeks, and LDL-C levels in the body were observed compared with placebo. RESULTS On average, LDL-C was reduced by approximately 55%-75% at weeks 10 and 12 compared to placebo. [1]
Storage	store at low temperature \| -20°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Keywords	Threonine proteases \| Serine proteases \| Serine endopeptidases \| Ser/Thr Protease \| Repatha \| PCSK9 \| LDLR \| Inhibitor \| inhibit \| hypercholesterolemia \| Evolocumab \| atherosclerotic cardiovascular disease \| AMG-145 \| AMG145 \| AMG 145
Inhibitors Related	Ethyl palmitate \| Naringin dihydrochalcone \| Kojic acid \| Hydroxychloroquine \| Fumaric acid \| Imidazole \| Diethylmaleate \| Chloroquine phosphate \| Glucosamine \| N,N-Dimethylacetamide \| Anethole \| Diallyl disulfide

show more

Company Profile Introduction

You may like

Recommended supplier

MSDS|CAS|CAS DataBase|Pricacy|Terms|About Us|New Products| Contact us|Computer Version
Chemical Book